RCUS
HealthcareArcus Biosciences, Inc. · Biotechnology · $2B
What is Arcus Biosciences, Inc.?
Arcus Biosciences is a clinical-stage biopharmaceutical company focused entirely on developing cancer therapies. Headquartered in Hayward, California, the company has built a pipeline targeting multiple immunological pathways involved in tumor growth.
Arcus generates no commercial revenue yet — its business model centers on advancing a portfolio of oncology drug candidates through clinical trials. The company collaborates with major partners including AstraZeneca and Taiho Pharmaceutical to co-develop and potentially commercialize its therapies. Revenue, if it comes, would flow from milestone payments, licensing agreements, and eventual drug sales. Until regulatory approvals are secured, the company remains dependent on partnership funding and capital markets.
Arcus Biosciences was incorporated in 2015 and is headquartered in Hayward, California.
- Etrumadenant — dual adenosine receptor antagonist in Phase 1b/2 trials
- Zimberelimab — anti-PD-1 antibody in Phase 1b monotherapy trial
- Domvanalimab — anti-TIGIT antibody in Phase 2/3 non-small cell lung cancer studies
- Quemliclustat — CD73 inhibitor in Phase 1/1b for pancreatic cancer
- AB521 — oral HIF-2a inhibitor in Phase 1 for von Hippel-Lindau disease
Is RCUS a Good Stock to Buy?
UQS Score rates RCUS as Poor overall, reflecting the early-stage nature of its business and the significant uncertainties that come with a pre-commercial oncology pipeline.
Among the five pillars, Risk stands out as the relative bright spot — suggesting the company's financial structure carries less near-term distress risk than many clinical-stage peers. This is meaningful for investors evaluating runway and downside scenarios.
Quality, Moat, and Growth all register as Weak, which is typical for companies with no approved products and no recurring revenue. Valuation is rated Elevated, meaning the current market price may already reflect optimistic clinical outcomes.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does RCUS pay dividends?
No — Arcus Biosciences, Inc. does not currently pay a dividend.
Arcus Biosciences does not pay a dividend, which is standard for clinical-stage biopharmaceutical companies. All available capital is directed toward funding clinical trials, research operations, and partnership activities. Investors in RCUS are betting on pipeline success rather than income generation — dividend payments are unlikely until the company reaches sustained commercial profitability.
When does RCUS report earnings?
Arcus Biosciences reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-commercial company, quarterly reports focus on cash position, operating expenses, and clinical trial progress rather than product revenue. Partnership milestones and collaboration updates tend to be the most market-moving disclosures each quarter.
For the most recent quarter's results and upcoming reporting dates, visit Arcus Biosciences' investor relations page directly.
RCUS Price History
-1.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Arcus Biosciences, Inc.?
Based on Arcus Biosciences, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
RCUS Long-term Outlook
The fundamental outlook for RCUS hinges almost entirely on clinical trial outcomes rather than organic business momentum. With Growth rated Weak, near-term catalysts are binary — trial readouts can shift the investment case dramatically in either direction. The Good Risk rating provides some comfort around financial stability, but the Elevated Valuation label suggests the market may already be pricing in favorable scenarios. Investors should weigh the pipeline's breadth against the long timelines and capital requirements typical of oncology drug development.
Growth drivers
- Potential Phase 3 data readouts for Domvanalimab in non-small cell lung cancer
- Expanded collaboration milestones from AstraZeneca and other partners
- Regulatory progress across multiple pipeline candidates in distinct cancer indications
Key risks
- Clinical trial failures could eliminate value across multiple pipeline assets simultaneously
- Elevated Valuation leaves limited margin of safety if trial results disappoint
- Ongoing cash burn requires continued access to capital markets or partnership funding
RCUS vs Peers
Arcus operates in a competitive clinical-stage oncology space alongside other development-focused biopharmaceutical companies.
Ultragenyx focuses on rare genetic diseases rather than oncology, giving it a distinct regulatory pathway and a partially commercialized product portfolio.
Kodiak concentrates on retinal disease treatments, operating in a therapeutic area entirely separate from Arcus's cancer immunology focus.
Ascentage is a clinical-stage oncology company like Arcus, but with a pipeline centered on apoptosis-regulating targets rather than immune checkpoint pathways.
Frequently Asked Questions
What does Arcus Biosciences do?
Arcus Biosciences is a clinical-stage company developing cancer immunotherapy drugs. Its pipeline targets multiple biological pathways — including adenosine receptors, PD-1, TIGIT, and CD73 — that tumors use to evade the immune system. The company has no approved products yet and funds operations primarily through partnerships and capital raises.
Does RCUS pay dividends?
No, Arcus Biosciences does not pay a dividend. Clinical-stage biopharmaceutical companies typically reinvest all available capital into research and development. A dividend is unlikely until the company achieves sustained commercial revenue from an approved product.
When does RCUS report earnings?
Arcus Biosciences follows a standard quarterly reporting schedule. Because the company has no product revenue, reports focus on cash runway, operating expenses, and pipeline updates. Check the Arcus Biosciences investor relations page for the current reporting calendar.
Is RCUS a good stock to buy?
UQS Score rates RCUS as Poor overall, driven by Weak scores across Quality, Moat, and Growth pillars. The Risk pillar is the relative strength. Whether RCUS suits an investor depends on their tolerance for binary clinical outcomes and pre-commercial risk. The full pillar breakdown is available to UQS Pro members.
Is RCUS overvalued?
The UQS Valuation pillar for RCUS is rated Elevated, suggesting the current market price may already reflect optimistic assumptions about pipeline success. For a company with no approved products, valuation is inherently speculative and tied to clinical trial probabilities rather than current earnings.
How does RCUS compare to its competitors?
Arcus competes in the broader clinical-stage biopharmaceutical space. Compared to peers like Ultragenyx and Ascentage Pharma, Arcus is distinguished by its focus on cancer immunology and its collaboration with AstraZeneca. UQS Pro members can view side-by-side pillar comparisons for a more structured view.
What is RCUS's market cap bracket?
RCUS is classified as a mid-cap stock. This places it in a range where institutional interest is meaningful but liquidity and analyst coverage may be less extensive than large-cap peers in the healthcare sector.
Who founded Arcus Biosciences?
Arcus Biosciences was founded by Terry Rosen and Juan Jaen, both experienced drug discovery scientists. The company was incorporated in 2015 and has grown its pipeline through internal research and external collaborations. Founding details are widely available through public company filings.
Is RCUS a long-term buy?
As a long-term quality indicator, UQS rates RCUS as Poor — reflecting the absence of a durable competitive moat, no current revenue base, and weak growth metrics. Long-term value creation depends almost entirely on clinical success, which carries substantial uncertainty. Pro members can review the full pillar profile to assess fit with their investment criteria.
What is the main competitive advantage of Arcus Biosciences?
Arcus's potential edge lies in its multi-target approach to cancer immunology and its partnership with AstraZeneca, which provides both validation and funding. However, the UQS Moat pillar rates this advantage as Weak, reflecting that no approved product yet creates a defensible market position.
What sector does RCUS belong to?
RCUS belongs to the Healthcare sector, specifically within clinical-stage biopharmaceuticals. This sub-segment is characterized by high risk, long development timelines, and the potential for outsized returns if drug candidates receive regulatory approval.
Unlock Full RCUS Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics and trend data
- ✓Compare RCUS against sector peers side by side
- ✓Track pipeline risk through the UQS Risk pillar detail
- ✓Get the full valuation context behind the Elevated rating
- ✓Explore curated screeners for clinical-stage healthcare stocks
Pro Analysis
RCUS — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 21.1 | 8.7 | 14.0 | 22.8 | 72.5 | 0.0 | +0.1 |
| Apr 2, 2026 | 21.0 | 8.7 | 14.0 | 22.8 | 71.6 | 0.0 | — |
RCUS — Pillar Breakdown
Quality
— 8.7/100 (25%)Arcus Biosciences, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 22.8/100 (20%)Arcus Biosciences, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 72.5/100 (15%)Arcus Biosciences, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Arcus Biosciences, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 14/100 (25%)Arcus Biosciences, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for RCUS.
Score Composition
Financial Data
More Stock Analysis
How is the RCUS UQS Score Calculated?
The UQS (Unified Quality Score) for Arcus Biosciences, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Arcus Biosciences, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Arcus Biosciences, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.